Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 10—October 2006
Dispatch

ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease

Erik R. Dubberke*Comments to Author , Kimberly Reske*, L. Clifford McDonald†, and Victoria Fraser*‡
Author affiliations: *Washington University in St. Louis–School of Medicine, Saint Louis, Missouri, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Barnes-Jewish Hospital, Saint Louis, Missouri, USA

Main Article

Table 2

Comparison of antimicrobial treatment for Clostridium difficile–associated disease among patient admissions with a positive C. difficile–toxin assay (CDTA+) and patients without a positive toxin assay but with ICD-9 code for C. difficile disease (CDTA–/ICD9+) (categories not mutually exclusive)

Treatment CDTA+, n = 662 (%) CDTA–/ICD9+, n= 239 (%) Odds ratio p value
Any treatment for CDAD 607 (92) 214 (90) 0.78 0.35
Metronidazole 591 (89) 187 (78) 0.43 <0.01
Oral vancomycin 130 (20) 75 (31) 1.87 <0.01
Oral vancomycin and metronidazole 114 (17) 48 (20) 1.21 0.32

Main Article

Page created: November 10, 2011
Page updated: November 10, 2011
Page reviewed: November 10, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external